NCT02391727View on ClinicalTrials.gov

Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions
Colon Cancer, Breast Cancer, Cancer of the Head and Neck
Interventions
BIOLOGICAL

SYN004

subjects who have received effective treatment for their cancers are eligible

Trial Locations (2)

63110

Washington University Medical Center, St Louis

70121

Ochsner Medical Center, New Orleans

All Listed Sponsors
lead

Synermore Biologics Co., Ltd.

INDUSTRY

NCT02391727 - Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter